Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

• প্রধান লেখক: Andreas Pinter (লেখক), Kilian Eyerich (লেখক), Antonio Costanzo (লেখক), Alyssa Garrelts (লেখক), Christopher Schuster (লেখক), Can Mert (লেখক), Anastasia Lampropoulou (লেখক), Konstantinos Fotiou (লেখক), Julia-Tatjana Maul (লেখক), Kim A. Papp (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

AbstractPurpose Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data from the Psoriasis Study of Health Outcomes (PSoH...